Corporate Banner
Satellite Banner
Technology
Networks
Scientific Communities
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Novasep and instrAction Expand Alliance to Include Taxane Purification

Published: Wednesday, February 09, 2011
Last Updated: Wednesday, February 09, 2011
Bookmark and Share
Companies will develop solutions to change manufacturing paradigm for new and generic anti-cancer compounds.

Novasep, and instrAction announces they have expanded their worldwide strategic alliance to include the purification of taxanes, a well-known class of anti-cancer compounds.

This extended collaboration enables Novasep to develop and operate or supply optimized large-scale chromatography processes for cost-effective purification of taxane-based active pharmaceutical ingredients (APIs) and intermediates. The two companies announced a strategic alliance covering non-chiral chromatography in July 2010.

The extended relationship means Novasep adds enhanced taxane anti-cancer compound capabilities to its extensive range of manufacturing solutions for life science industries.

Novasep customers will benefit from the collaboration as they will be able to access a cost-effective one-step purification solution for their taxane-based APIs. A large number of clinical trials involve paclitaxel and docetaxel, two of the leading anti-cancer APIs marketed today, and approved for the treatment of breast, ovarian, prostate, non small cell lung cancers, etc., and also new taxanes, taxane conjugates or combinations between taxanes and other APIs.

instrAction has synthesized a family of API-selective stationary phases among their 3,000-phase library based on its proprietary technology, which have shown a strong potential for the purification of various taxanes. Access to instrAction’s technology means Novasep can develop a multi-step synthesis or semi-synthesis, and optimize purification steps using instrAction's set of taxane-selective chromatographic stationary phases. Novasep can then scale up the optimized process and produce the API for clinical and commercial purposes.

Alternatively, Novasep can supply the developed process to its customers with performance guarantees, integrating Novasep’s leading Prochrom® HPLC columns and systems and instrAction’s selective stationary phases. For mature or generic APIs, Novasep and instrAction can additionally file and license application patents to extend the protection of their customers’ products.

Novasep develops and manufactures its customers’ taxane-based APIs and advanced intermediates at its FDA inspected and SafeBridge certified Le Mans site in France, specialized in highly potent API (HPAPI) synthesis and purification.

“Thanks to instrAction’s highly selective chromatographic stationary phases and Novasep’s 20 years experience in taxane synthesis and purification, we are looking to see a paradigm shift in solutions for our customers worldwide as a result of this collaboration,” says René De Vaumas, executive vice president in charge of Novasep Synthesis’ business development.

“We are delighted about our extended collaboration with Novasep, a leader in taxane synthesis and purification,” said Dr. Thomas Schwarz, CEO of instrAction GmbH. “The cooperation with Novasep in the field of taxane purification is a further important milestone to implement the instrAction technology in industrial downstream processes. We are very confident that it will be broadly applied to the industrial purification of APIs in the future.”


Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,500+ scientific posters on ePosters
  • More Than 3,700+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Novasep Invests €10M to Reinforce its Bioconjugation Services
Expansion marks the company’s readiness for full range Antibody Drug Conjugates CMO services.
Thursday, June 25, 2015
Novasep Further Strengthens Management Team
Pierre-Louis Mikus joins as chief legal officer and Bertrand Waymel is promoted to group human resources director.
Wednesday, May 06, 2015
Novasep and Celladon Execute MYDICAR API Supply Agreement
An innovative, genetically-targeted enzyme replacement therapy based on AAV1/SERCA2a.
Thursday, March 26, 2015
Novasep & Celladon Partner
Novasep has entered into an agreement with Celladon, to commercially biomanufacture Celladon’s Mydicar API.
Tuesday, February 24, 2015
Novasep Enters into an Agreement with Celladon
Company selected to commercially biomanufacture Celladon's Mydicar API.
Thursday, February 19, 2015
Novasep Opens New Office in Thailand
Novasep’s extended presence in South East Asia strengthens the company’s ability to address growing needs in the region’s food and feed markets.
Saturday, December 27, 2014
Novasep to Sell its Bahamian Plant to Local Investor
Company has completed the sale of the Bahamian facility and related business of its fully-owned subsidiary, Pharmachem.
Thursday, October 09, 2014
Novasep Passes FDA Inspections on Two Sites
Novasep wins approval to produce new molecular entity for US market.
Thursday, July 24, 2014
Novasep’s €4 M ADC Manufacturing Plant Extension Commissioned
The new Highly Potent API manufacturing capacity at the Le Mans facility will boost Novasep’s ability to meet customer demand for producing anti-cancer therapies.
Friday, May 16, 2014
Novasep Reports Full Year 2013 Results
Results show strong growth and beating guidance.
Friday, March 28, 2014
Novasep Appoints CEO Michel Spagnol as Chairman
Novasep presents strategic developments.
Wednesday, March 05, 2014
Novasep Expands and Opens Subsidiary in India
Subsidiary to meet India’s increasing need for high efficacy processes for its fast growing food and feed industries.
Friday, February 14, 2014
Novasep Attracts Top Talent to Complete its Executive Team
Thierry Van Nieuwenhove, a seasoned CMO top executive, joins Novasep as president of the Synthesis Business Unit.
Monday, January 20, 2014
Novasep Expands and Opens Subsidiary in India
Novasep Process Engineering Services PVT LTD will meet India’s increasing need for high efficacy processes for its fast growing food and feed industries.
Monday, December 16, 2013
Novasep Opens Indian Subsidiary
New office will meet India’s increasing need for high efficacy processes for its fast growing food and feed industries.
Tuesday, December 10, 2013
Scientific News
The Changing Tides of the In Vitro Diagnostics Market
With the increasing focus in personalized medicine, diagnostics plays a crucial role in patient monitoring.
LaVision BioTec Reports on the Neuro Research on the Human Brain After Trauma
Company reports on the work of Dr Ali Ertürk from the Institute for Stroke and Dementia Research at LMU Munich.
NIH Study Shows No Benefit of Omega-3 Supplements for Cognitive Decline
Research was published in the Journal of the American Medical Association.
Less May Be More in Slowing Cholera Epidemics
Mathematical model shows more cases may be prevented and more lives saved when using one dose of cholera vaccine instead of recommended two doses.
Investigating the Vape
Expert independent review concludes that e-cigarettes have potential to help smokers quit.
NIH Launches Human RSV Study
Study aims to understand infection in healthy adults to aid development of RSV medicines, vaccines.
Researchers Discover Synthesis of a New Nanomaterial
Interdisciplinary team creates biocomposite for first time using physiological conditions.
Poor Survival Rates in Leukemia Linked to Persistent Genetic Mutations
For patients with an often-deadly form of leukemia, new research suggests that lingering cancer-related mutations – detected after initial treatment with chemotherapy – are associated with an increased risk of relapse and poor survival.
Flu Remedies Help Combat E. coli Bacteria
Physiologists from the University of Zurich have now discovered why the intestinal bacterium Escherichia coli (E. coli) multiplies heavily and has an inflammatory effect.
Marijuana Genome Unraveled
A study by Canadian researchers is providing a clearer picture of the evolutionary history and genetic organization of cannabis, a step that could have agricultural, medical and legal implications for this valuable crop.
Scroll Up
Scroll Down
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,500+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
3,700+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FREE!